Corvus Pharmaceuticals, Inc. (CRVS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CRVS currently has 90M outstanding shares. with significant dilution risk as 190M authorized shares could dilute existing holders by 210.9%. The company has significantly diluted shareholders by 85.94% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 90.0M shares outstanding |
90M | 190M |
| Mar 12, 2026 |
10-K filing | 79.7M shares outstanding |
80M | 190M |
| Nov 04, 2025 |
10-Q filing | 74.7M shares outstanding |
75M | 190M |
| Aug 07, 2025 |
10-Q filing | 77.8M shares outstanding |
78M | 190M |
| May 08, 2025 |
10-Q filing | 72.1M shares outstanding |
72M | 190M |
| Mar 25, 2025 |
10-K filing | 49.0M shares outstanding |
49M | 190M |
| Dec 18, 2024 |
8-K filing: Samlyn Capital, a holder of warrants to purchase 3,633,978 shares of common stock of Corvus Pharmaceuticals, Inc., has delivered exercise notices with respect to all of its warrants, which is expected to result in cash proceeds to the Company of approximately $12.7 million. ($12.7M proceeds) |
67M | 190M |
| Nov 12, 2024 |
10-Q filing | 66.7M shares outstanding |
67M | 190M |
| Aug 06, 2024 |
S-3 filing: Corvus Pharmaceuticals, Inc. is filing an S-3 form to offer and sell up to $200,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
63M | 190M |
| Aug 06, 2024 |
10-Q filing | 59.7M shares outstanding |
60M | 190M |
| May 07, 2024 |
10-Q filing | 49.0M shares outstanding |
49M | 150M |
| Mar 19, 2024 |
10-K filing | 48.0M shares outstanding |
48M | 150M |
| Nov 07, 2023 |
10-Q filing | 49.0M shares outstanding |
49M | 150M |
| Aug 08, 2023 |
10-Q filing | 47.5M shares outstanding |
47M | 150M |
| May 08, 2023 |
10-Q filing | 46.6M shares outstanding |
47M | 150M |
| Mar 29, 2023 |
S-3 filing: Corvus Pharmaceuticals, Inc. is offering up to $100,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
47M | 150M |
| Mar 28, 2023 |
10-K filing | 46.6M shares outstanding |
47M | 16M |
| Nov 03, 2022 |
10-Q filing | 46.6M shares outstanding |
47M | 16M |
| Aug 08, 2022 |
10-Q filing | 46.6M shares outstanding |
47M | 16M |
| May 05, 2022 |
10-Q filing | 46.6M shares outstanding |
47M | 16M |
| Mar 10, 2022 |
10-K filing | 46.6M shares outstanding |
47M | 16M |
| Nov 01, 2021 |
10-Q filing | 46.5M shares outstanding |
47M | 16M |
| Aug 02, 2021 |
10-Q filing | 42.4M shares outstanding |
42M | 16M |
| Apr 29, 2021 |
10-Q filing | 38.3M shares outstanding |
38M | 16M |
| Mar 25, 2021 |
10-K filing | 28.4M shares outstanding |
28M | 16M |
| Feb 17, 2021 |
8-K filing: Corvus Pharmaceuticals, Inc. completed the sale and issuance of 9,783,660 shares of Common Stock at a price of $3.50 per share to the public, including the underwriters' partial exercise of their option, receiving net proceeds of approximately $31.8 million. ($31.8M proceeds) |
28M | 16M |
| Oct 29, 2020 |
10-Q filing | 28.1M shares outstanding |
28M | 16M |
| Jul 30, 2020 |
10-Q filing | 28.0M shares outstanding |
28M | 16M |
| Apr 30, 2020 |
10-Q filing | 28.0M shares outstanding |
28M | 16M |
| Mar 09, 2020 |
S-3 filing: Corvus Pharmaceuticals, Inc. may offer and sell up to $200,000,000 in the aggregate of common stock and preferred stock from time to time in one or more offerings. |
28M | 16M |
| Mar 09, 2020 |
10-K filing | 29.3M shares outstanding |
29M | 16M |